Celltrion Inc
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 648
- Registration Number
- NCT03789292
- Locations
- π§π¬
National Multiprofile Transport Hospital Tsar Boris III, Sofia, Bulgaria
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 270
- Registration Number
- NCT03707535
- Locations
- π¨π³
Peking Union Medical College Hospital, Beijing, China
To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 689
- Registration Number
- NCT03676192
- Locations
- π°π·
Chung-Ang University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 228
- Registration Number
- NCT03511066
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Korea, Republic of
CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 218
- Registration Number
- NCT03446976
- Locations
- πΊπΈ
PPD Development, LP, Austin, Texas, United States
To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 141
- Registration Number
- NCT03247673
- Locations
- π°π·
Inje University Busan Paik Hospital, Busan, Korea, Republic of
π°π·Inha University Hospital, Incheon, Korea, Republic of
π°π·Seoul St.Mary's hospital, Seoul, Korea, Republic of
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 407
- Registration Number
- NCT03147248
- Locations
- π°π·
Hanyang University Medical Center, Seoul, Korea, Republic of
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 181
- Registration Number
- NCT02883452
- Locations
- π°π·
Yeungnam University Hospital, Daegu, Korea, Republic of
Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 70
- Registration Number
- NCT02665637
- Locations
- πΊπΈ
PPD Phase I Clinic, Austin, Texas, United States
An Observational Study to Evaluate Safety and Efficacy of Remsimaβ’ in Patients With RA
Terminated
- Conditions
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 248
- Registration Number
- NCT02557295
Β© Copyright 2024. All Rights Reserved by MedPath